SMJ-56-567.Pdf
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
35 Cyproterone Acetate and Ethinyl Estradiol Tablets 2 Mg/0
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrCYESTRA®-35 cyproterone acetate and ethinyl estradiol tablets 2 mg/0.035 mg THERAPEUTIC CLASSIFICATION Acne Therapy Paladin Labs Inc. Date of Preparation: 100 Alexis Nihon Blvd, Suite 600 January 17, 2019 St-Laurent, Quebec H4M 2P2 Version: 6.0 Control # 223341 _____________________________________________________________________________________________ CYESTRA-35 Product Monograph Page 1 of 48 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................................. 3 INDICATION AND CLINICAL USE ..................................................................................................... 3 CONTRAINDICATIONS ........................................................................................................................ 3 WARNINGS AND PRECAUTIONS ....................................................................................................... 4 ADVERSE REACTIONS ....................................................................................................................... 13 DRUG INTERACTIONS ....................................................................................................................... 16 DOSAGE AND ADMINISTRATION ................................................................................................ 20 OVERDOSAGE .................................................................................................................................... -
Therapeutic Medications Against Diabetes: What We Have and What We Expect
Advanced Drug Delivery Reviews 139 (2019) 3–15 Contents lists available at ScienceDirect Advanced Drug Delivery Reviews journal homepage: www.elsevier.com/locate/addr Therapeutic medications against diabetes: What we have and what we expect Cheng Hu a,b, Weiping Jia a,⁎ a Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Key Clinical Center for Metabolic Diseases, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 600 Yishan Road, Shanghai 200233, People's Republic of China b Shanghai Jiao Tong University Affiliated Sixth People's Hospital South Campus, 6600 Nanfeng Road, Shanghai 200433, People's Republic of China article info abstract Article history: Diabetes has become one of the largest global health and economic burdens, with its increased prevalence and Received 28 June 2018 high complication ratio. Stable and satisfactory blood glucose control are vital to reduce diabetes-related compli- Received in revised form 1 September 2018 cations. Therefore, continuous attempts have been made in antidiabetic drugs, treatment routes, and traditional Accepted 27 November 2018 Chinese medicine to achieve better disease control. New antidiabetic drugs and appropriate combinations of Available online 5 December 2018 these drugs have increased diabetes control significantly. Besides, novel treatment routes including oral antidia- betic peptide delivery, nanocarrier delivery system, implantable drug delivery system are also pivotal for diabetes Keywords: fi Diabetes control, with its greater ef ciency, increased bioavailability, decreased toxicity and reduced dosing frequency. Treatment Among these new routes, nanotechnology, artificial pancreas and islet cell implantation have shown great poten- Drug delivery tial in diabetes therapy. Traditional Chinese medicine also offer new options for diabetes treatment. -
Therapeutic Effect of Antibiotics in the Compromised Host an Experimental Study
THERAPEUTIC EFFECT OF ANTIBIOTICS IN THE COMPROMISED HOST AN EXPERIMENTAL STUDY THERAPEUTISCH EFFECT VAN ANTIBIOTICA IN DE GASTHEER MET VERMINDERDE WEERSTAND EEN EXPERIMENTELE STUDIE PROEFSCHRIFT TER VERKRDGING VAN DE GRAAD VAN DOCTOR AAN DE ERASMUS UNIVERSITEIT ROTTERDAM OP GEZAG VAN DE RECTOR MAGNIFICUS PROF. DR. A.H.G. RINNOOY KAN EN VOLGENS BESLUIT VAN HET COLLEGE VAN DEKANEN. DE OPENBARE VERDEDIGING ZAL PLAATSVINDEN OP WOENSDAG 14 DECEMBER 1988 OM 15.45 UUR DOOR ROBERT ROOSENDAAL GEBOREN TE ROERMOND Gedrukt bij Offsetdrukkerij Kanters B.V., Alblasserdam 1988 PROMOTIECOMMISSIE: Promotor: Prof. Dr. M.F. Michel Overige leden: Prof. Dr. J.WM. van der Meer Prof Dr. H.J. Neijens Prof. Dr. D. van der Waaij Co-promotor: Mw. Dr. I.A.J.M. Bakker-Woudenberg CONTENTS CHAPTER 1: GENERAL INTRODUCTION 7 CHAPTER 2: EXPERIMENTAL DESIGN 11 CHAPTER 3: IMPACT OF THE DOSAGE SCHEDULE ON THE THERAPEUTIC EFFECT OF ANTIBIOTIC IN RELATION TO THE SEVERITY OF INFECTION efficacy of ceftazidime in immunocompetent rats with Klebsiella pneumoniae pneumonia and septicemia 23 CHAPTER 4: IMPACT OF THE DOSAGE SCHEDULE ON THE THERAPEUTIC EFFECT OF ANTIBIOTIC IN RELATION TO HOST DEFENSE MECHANISMS efficacy of ceftazidime in immunocompetent versus leukopenic rats with Klebsiella pneumoniae pneumonia and septicemia 31 CHAPTER 5: IMPACT OF THE DOSAGE SCHEDULE ON THE THERAPEUTIC EFFECT IN RELATION TO THE KINETICS OF ANTIBACTERIAL ACTIVITY IN VITRO AND IN VIVO FOR DIFFERENT CLASSES OF ANTIBIOTICS efficacy of ceftazidime, gentamicin, and ciprofloxacin in leukopenic rats with Klebsiella pneumoniae pneumonia and septicemia 39 CHAPTER 6: THERAPEUTIC EFFECT OF ANTIBIOTIC IN RELATION TO THE DURATION OF INFECTION AND THE BACTERIAL GROWTH RATE efficacy of ceftazidime, gentamicin, and ciprofloxacin in leukopenic rats with Klebsiella pneumoniae pneumonia and septicemia 53 CHAPTER 7: GENERAL DISCUSSION AND CONCLUSIONS 69 REFERENCES 81 SUMMARY 93 SAMENVATTING 99 DANKWOORD 105 CURRICULUM VITAE 107 APPENDIX PAPER I Roosendaal R, Bakker-Woudenberg IA.JM, van den Berg JC, Michel MF. -
NSAIDS Use of Otcs Last Updated 07/10
Adopted: 6/98 Revised: 2/05, 7/10 NSAIDs—Use of Over-the-Counter Nonsteroidal Anti-Inflammatory Drugs and Analgesics Over-the-counter (OTC) nonsteroidal anti-inflammatory drugs (NSAIDs) are used to control pain and inflammation in a variety of musculoskeletal conditions, including arthritis, low back pain and sports injuries. The main objective of this protocol is to review NSAIDs that are commonly used in clinical management of musculoskeletal conditions. Dosage, side effects, contraindications, and interactions with other medications are presented, as well as a strategy for decision-making. Although not an NSAID, the analgesic acetaminophen is also discussed. Because treatment with NSAIDs may mask or confuse the benefit of other therapies, it may be prudent to delay use of NSAIDs in some cases until the effectiveness of alternative therapy is determined. BACKGROUND Reducing Pain and Inflammation Limitations of Evidence Nonsteroidal anti-inflammatory drugs (NSAIDs) are Scientific evidence from drug trials may not commonly employed in the pharmacological apply to everyone taking a particular drug. For management of pain and inflammation. These example, minority groups, children, the drugs work by inhibiting enzymes called elderly, and persons at increased risk of cyclooxygenase 1 and 2 (COX 1-2). The COX 1-2 adverse events are often deliberately excluded enzymes are responsible for the production of from trials. Furthermore, therapeutic benefits prostaglandins, hormone-like substances involved of drugs and adverse reactions are not in inflammation and pain (Prisk 2003). NSAIDs have measured using comparable scales. Finally, been routinely used for the initial onset, drugs tend to be used for a wider range of continued relief, and re-injury or exacerbations of indications than those for which they are musculoskeletal pain. -
Principles of Pharmacology
© Jones & Bartlett Learning, LLC © Jones & Bartlett Learning, LLC manning/Shutterstock © Sofi NOT FOR SALE OR DISTRIBUTION NOT FOR2 SALE OR DISTRIBUTION Principles of Pharmacology © Jones & Bartlett Learning, LLC Laura Williford Owens,© Robin Jones Webb & Corbett, Bartlett Learning, LLC NOT FOR SALE OR DISTRIBUTIONTekoa L. King NOT FOR SALE OR DISTRIBUTION © Jones & Bartlett Learning, LLC © Jones & Bartlett Learning, LLC NOT FOR SALE OR DISTRIBUTION NOT FOR SALE OR DISTRIBUTION © Jones & Bartlett Learning, LLC © Jones & Bartlett Learning, LLC NOT FOR SALE✜ Chapter OR DISTRIBUTION Glossary NOT FOR SALE OR DISTRIBUTION exchange of drugs between the systemic circulation Absorption Movement of drug particles from the gastro- and the circulation in the central nervous system. intestinal tract to the systemic circulation by passive Chronobiology (chronopharmacology) Use of knowledge of cir- absorption, active transport, or pinocytosis. cadian rhythms to time administration of drugs for © Jones & Bartlett Learning, LLC © Jones & Bartlett Learning, LLC Affinity Degree of attraction between a drug and a recep- maximum benefi t and minimal harm. tor. Th e greater NOTthe attraction, FOR SALE the greater OR DISTRIBUTIONthe extent Clearance Measure of the body’sNOT ability FOR to SALE eliminate OR a drug.DISTRIBUTION of binding. Competitive antagonist Drug or ligand that reversibly binds Agonist Drug that activates a receptor when bound to that to receptors at the same receptor site that agonists use receptor. (active site) without activating the receptor to initiate Agonist–antagonist© Jones & BartlettDrug that Learning,has agonist properties LLC for one a reaction.© Jones & Bartlett Learning, LLC NOTopioid FOR receptor SALE and antagonist OR DISTRIBUTION properties for a diff erent CytochromeNOT P-450 FOR (CYP450) SALE Generic OR name DISTRIBUTION for the family of type of opioid receptor. -
Reference ID: 4786649
HIGHLIGHTS OF PRESCRIBING INFORMATION Hypertension: Patients taking some antihypertensive medications may These highlights do not include all the information needed to use have impaired response to these therapies when taking NSAIDs. LICART™ safely and effectively. See full prescribing information for Monitor blood pressure (5.4, 7) LICART. Heart Failure and Edema: Avoid use of LICART in patients with severe LICART™ (diclofenac epolamine) topical system heart failure unless benefits are expected to outweigh risk of worsening Initial U.S. Approval: 1988 heart failure (5.5) WARNING: RISK OF SERIOUS CARDIOVASCULAR and Renal Toxicity: Monitor renal function in patients with renal or hepatic GASTROINTESTINAL EVENTS impairment, heart failure, dehydration, or hypovolemia. Avoid use of See full prescribing information for complete boxed warning. LICART in patients with advanced renal disease unless benefits are expected to outweigh risk of worsening renal function (5.6) Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased Anaphylactic Reactions: Seek emergency help if an anaphylactic risk of serious cardiovascular thrombotic events, including reaction occurs (5.7) myocardial infarction and stroke, which can be fatal. This risk may Exacerbation of Asthma Related to Aspirin Sensitivity: LICART is occur early in the treatment and may increase with duration of use contraindicated in patients with aspirin-sensitive asthma. Monitor (5.1) patients with preexisting asthma (without aspirin sensitivity) (5.8) LICART is contraindicated in the setting of coronary artery bypass Serious Skin Reactions: Discontinue LICART at first appearance of skin graft (CABG) surgery. (4, 5.1) rash or other signs of hypersensitivity (5.9) NSAIDs cause an increased risk of serious gastrointestinal (GI) Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): adverse events including bleeding, ulceration, and perforation of the Discontinue and evaluate clinically (5.10 ). -
Antimicrobial Drugs 601
Chapter 14 | Antimicrobial Drugs 601 Chapter 14 Antimicrobial Drugs Figure 14.1 First mass produced in the 1940s, penicillin was instrumental in saving millions of lives during World War II and was considered a wonder drug.[1] Today, overprescription of antibiotics (especially for childhood illnesses) has contributed to the evolution of drug-resistant pathogens. (credit left: modification of work by Chemical Heritage Foundation; credit right: modification of work by U.S. Department of Defense) Chapter Outline 14.1 History of Chemotherapy and Antimicrobial Discovery 14.2 Fundamentals of Antimicrobial Chemotherapy 14.3 Mechanisms of Antibacterial Drugs 14.4 Mechanisms of Other Antimicrobial Drugs 14.5 Drug Resistance 14.6 Testing the Effectiveness of Antimicrobials 14.7 Current Strategies for Antimicrobial Discovery Introduction In nature, some microbes produce substances that inhibit or kill other microbes that might otherwise compete for the same resources. Humans have successfully exploited these abilities, using microbes to mass-produce substances that can be used as antimicrobial drugs. Since their discovery, antimicrobial drugs have saved countless lives, and they remain an essential tool for treating and controlling infectious disease. But their widespread and often unnecessary use has had an unintended side effect: the rise of multidrug-resistant microbial strains. In this chapter, we will discuss how antimicrobial drugs work, why microbes develop resistance, and what health professionals can do to encourage responsible use of antimicrobials. -
TERCONAZOLE VAGINAL CREAM 0.4% Rx Only
TERCONAZOLE- terconazole cream E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. ---------- TERCONAZOLE VAGINAL CREAM 0.4% Rx Only DESCRIPTION Terconazole vaginal cream 0.4% is a white to off-white, water washable cream for intravaginal administration containing 0.4% of the antifungal agent terconazole, cis-1-[p- [[2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4- yl]methoxy]phenyl]-4-isopropylpiperazine, compounded in a cream base consisting of butylated hydroxyanisole, cetyl alcohol, isopropyl myristate, polysorbate 60, polysorbate 80, propylene glycol, stearyl alcohol, and purified water. The structural formula of terconazole is as follows: Terconazole, a triazole derivative, is a white to almost white powder with a molecular weight of 532.47. It is insoluble in water; sparingly soluble in ethanol; and soluble in butanol. CLINICAL PHARMACOLOGY Absorption Following a single intravaginal application of a suppository containing 240 mg 14C- terconazole to healthy women, approximately 70% (range: 64 to 76%) of terconazole remains in the vaginal area during the suppository retention period (16 hours); approximately 10% (range: 5 to 16%) of the administered radioactivity was absorbed systemically over 7 days. Maximum plasma concentrations of terconazole occur 5 to 10 hours after intravaginal application of the cream or suppository. Systemic exposure to terconazole is approximately proportional to the applied dose, whether as the cream or suppository. The rate and extent of absorption of terconazole are similar in patients with vulvovaginal candidiasis (pregnant or non-pregnant) and healthy subjects. Distribution Terconazole is highly protein bound (94.9%) in human plasma and the degree of binding is independent of drug concentration over the range of 0.01 to 5 mcg/mL. -
The Pharmacologic Treatment of Depression
J Am Board Fam Pract: first published as 10.3122/15572625-11-2-127 on 1 March 1998. Downloaded from CLINICAL REVIEW The Pharmacologic Treatment of Depression Barbara A. Majeroni, MD, and Andrea Hess, PharmD Background. Family physicians often provide the first line of treatment for patients with depression. Many effective drugs are now available for the pharmacologic treatment of depression. Methods: We searched MEDLINE from 1991-96 under the topics of depressive disorders/treatment and antidepressant medications. Other sources were found by back-referencing from these references and from pharmacology texts. Results: Although antidepressants appear to be equally effective, selective serotonin reuptake inhibitors are frequently the drugs of choice because of their safety profile and less troublesome side effects. Conclusions: When prescribing antidepressant medications, the clinician must educate patients about potential side effects and about the amount of time that must be allowed for therapeutic efficacy. Drug interactions and concurrent medical conditions are important factors in the choice of an antidepressant. (J Am Board Fam Pract 1998;11:127-39.) Depression is a common finding in primary care care physicians who are treating major depressive practice, with a 6-month prevalence of 5.8 percent disorders with medication. and a lifetime prevalence of 17 percent in the United States. l Detection has been discussed else Classes of Antidepressants where.2 Once the diagnosis has been made, the A large selection of drugs is available in the United physician must determine the optimal treatment States for the treatment of depression (fable 1). plan for each patient. In cases of mild depression, Since all are effective, selection of a drug is based psychotherapy alone can be effective, but in mod on considerations of safety, tolerability, cost, and erate to severe depression, pharmacotherapy convenience of dosing. -
Diabetes Mellitus Treatment Using Herbal Drugs
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Advanced Research Journals Verma et al. DOI:10.5138/09750185.2181 International Journal of Phytomedicine 2018;10(1):1-10 Review Article Diabetes Mellitus Treatment Using Herbal Drugs 1 1 1 1* Sonia Verma , Madhu Gupta , Harvinder Popli and Geeta Aggarwal Abstract Diabetes mellitus is becoming a common metabolic disorder which has serious threat to public health in the world. There are chemicals and biochemical agent that helps in controlling diabetes but there is no permanent remedy available which helps to get recovered completely from this disorder. By conducting large number of research work, numerous traditional medicines have been found for diabetes. Substances and extracts isolated from different natural resources especially plants have always been a rich arsenal for controlling and treating diabetes problem and complication arising due to it. So this review helps the reader to understand the importance of various types of herbal and poly herbal formulations present traditionally which can be used to treat diabetes mellitus. Keywords: Diabetes mellitus; Herbal drugs; extract; traditional medicine; polyherbal Introduction Langerhans which are present in pancreas. Type 2 Diabetes mel- Diabetes mellitus is a non-infectious endocrine disorder which litus is known as insulin non dependent diabetes mellitus which is characterized by the disturbance in metabolism of carbohy- is temporary loss of β cell mass and it is due to genetic pre- drate and associated with hypoglycemia [1] [2] . It is linked disposition and mostly occur in obese persons and associated with developing of various serious diseases like micro vascu- with high blood pressure and high cholesterol levels. -
IBS-Monograph-2018.Pdf
SUPPLEMENT 1 see related editorial on page x American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome Alexander C. Ford, MB ChB, MD, FRCP1, Paul Moayyedi, BSc, MB ChB, PhD, MPH, FACG, FRCP, FRCPC, AGAF2, William D. Chey, MD, FACG, AGAF, FACP3, Lucinda A. Harris, MD, FACG4, Brian E. Lacy, MD, PhD, FACG5, Yuri A. Saito, MD, MPH, FACG6 and Eamonn M. M. Quigley, MD, MACG, FRCP, FACP, FRCPI7 for the ACG Task Force on Management of Irritable Bowel Syndrome Am J Gastroenterol https://doi.org/10.1038/s41395-018-0084-x INTRODUCTION IBS assumes considerable importance, therefore, not just for the Irritable bowel syndrome (IBS) is the most prevalent of the func- individual suferer, but for society at large. tional gastrointestinal disorders (FGIDs). Current estimates are Given the clinical heterogeneity that is a hallmark of the disor- that IBS afects up to 10–12% of adults in North America [1, 2]. der and the absence of a single efective therapy for all suferers, Although it can afect all individuals regardless of age, creed, or available therapies tend to focus on predominant symptomatol- gender, IBS is more common among women and is most com- ogy at presentation (i.e., altered bowel habits, abdominal pain, or monly diagnosed in younger individuals (<age 50) [2, 3]. IBS bloating) [4–6]. Based on their purported mode of action, many is characterized by recurrent abdominal pain and altered bowel pharmacological therapies for IBS developed in recent decades habits; bloating and distention frequently coexist. Te diagnosis have been directed towards those with a particular bowel habit, of IBS is made by taking a careful history, eliciting key symptoms, whether diarrhea or constipation. -
Amitriptyline FP 05-2014 Layout 1 5/2
7339 41.75x2.375 Amitriptyline FP 05-2014_Layout 1 5/2 Amitriptyline Hydrochloride Tablets, USP Suicidality and Antidepressant Drugs: Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of amitriptyline hydrochloride tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and cer- tain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the pre- scriber. Amitriptyline hydrochloride is not approved for use in pediatric patients. (See WARNINGS: Clinical Worsening and Suicide Risk, PRECAUTIONS: Information for Patients, and PRECAUTIONS: Pediatric Use) DESCRIPTION Amitriptyline HCl, a dibenzocycloheptadiene derivative, is a white, or practically white, odorless, crystalline compound which is freely soluble in water and alcohol. It is designated chemically as 10,11-Dihydro-N,N-dimethyl- 5H-dibenzo[a,d] cycloheptene-Δ5, γ-propylamine hydrochloride. It has the following structural formula: Each tablet for oral administration contains 10, 25, 50, 75, 100, or 150 mg amitriptyline hydrochloride.